M&A / Deals Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Pharmaceutical TechnologyVia the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.Infectious DiseaseRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) Pharmaceutical Technology Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study Related Stories M&A / Deals Gilead inks $140M API supply deal, tightening ties to Korean manufacturer pharminent May 22, 2026 M&A / Deals GBL joins CVC in 10.7bn takeover bid for Recordati pharminent May 22, 2026 M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn pharminent May 22, 2026
